Similar articles for PMID: 32893285

Year	Number of Results
1892	1
1999	1
2000	2
2001	2
2003	4
2004	2
2006	5
2007	4
2008	4
2009	5
2010	5
2011	17
2012	9
2013	5
2014	8
2015	5
2016	5
2017	11
2018	1
2019	6
2020	21
2021	14
2022	14
2023	4
2024	1

1

Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients.

Ishaqui AA, Khan AH, Sulaiman SA, Alsultan M, Khan I. Ishaqui AA, et al. Saudi Med J. 2020 Sep;41(9):1015-1021. doi: 10.15537/smj.2020.9.25249. Saudi Med J. 2020. PMID: 32893285 Free PMC article.

2

Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications.

Ishaqui A, Hayat Khan A, Sulaiman SAS, Taher Alsultan M, Khan I. Ishaqui A, et al. Expert Rev Anti Infect Ther. 2021 Sep;19(9):1165-1173. doi: 10.1080/14787210.2021.1889369. Epub 2021 Mar 5. Expert Rev Anti Infect Ther. 2021. PMID: 33567928

3

Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief.

Ishaqui AA, Khan AH, Sulaiman SAS, Alsultan MT, Khan I, Naqvi AA. Ishaqui AA, et al. Expert Rev Respir Med. 2020 May;14(5):533-541. doi: 10.1080/17476348.2020.1730180. Epub 2020 Feb 20. Expert Rev Respir Med. 2020. PMID: 32053044

4

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

Lee N, Hui DS, Zuo Z, Ngai KL, Lui GC, Wo SK, Tam WW, Chan MC, Wong BC, Wong RY, Choi KW, Sin WW, Lee EL, Tomlinson B, Hayden FG, Chan PK. Lee N, et al. Clin Infect Dis. 2013 Dec;57(11):1511-9. doi: 10.1093/cid/cit597. Epub 2013 Sep 17. Clin Infect Dis. 2013. PMID: 24046309 Clinical Trial.

5

Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.

Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Hiba V, et al. J Antimicrob Chemother. 2011 May;66(5):1150-5. doi: 10.1093/jac/dkr089. Epub 2011 Mar 9. J Antimicrob Chemother. 2011. PMID: 21393197

6

[Pandemic influenza in Russia: specific features of clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease].

Kolobukhina LV, Merkulova LN, Shchelkanov MIu, Burtseva EI, Lavrishcheva VV, Samokhvalov EI, Al'khovskiĭ SV, Prilipov AG, Proshina ES, Avdeev SN, Sutochnikova OA, Bazarova MV, Kelli EI, Tserukalova ND, Blank IA, Shestakova OM, Kolivashko ON, Arseneva TV, Ambrosi OE, Shul'diakov AA, Popov AF, Simakova AI, Malyshev NA, Chuchalin AG, L'vov DK. Kolobukhina LV, et al. Ter Arkh. 2011;83(9):48-53. Ter Arkh. 2011. PMID: 22145388 Clinical Trial. Russian.

7

Assessment of antiviral and antibiotic combination treatment in influenza-A H1N1 induced acute kidney injury among hospitalized patients.

Ishaqui AA, Khan AH, Syed Sulaiman SA, Alsultan MT, Khan I, Al Nami H. Ishaqui AA, et al. Pak J Pharm Sci. 2019 May;32(3 (Supplementary)):1225-1233. Pak J Pharm Sci. 2019. PMID: 31303595 Clinical Trial.

8

Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.

Viasus D, Paño-Pardo JR, Pachón J, Riera M, López-Medrano F, Payeras A, Fariñas MC, Moreno A, Rodríguez-Baño J, Oteo JA, Ortega L, Torre-Cisneros J, Segura F, Carratalà J; Novel Infl uenza A(H1N1) Study Group of the Spanish Network for Research in Infectious Diseases (REIPI). Viasus D, et al. Chest. 2011 Oct;140(4):1025-1032. doi: 10.1378/chest.10-2792. Epub 2011 Mar 17. Chest. 2011. PMID: 21415133

9

[A multicenter randomized controlled study of the efficacy and safety of oseltamivir in the treatment of influenza in a high risk population].

Lin JT, Yu XZ, Cui DJ, Chen XY, Zhu JH, Wang YZ, Wu XD, Gao H, Huo ZL, Zhu SH, Hu SL, Wang AX. Lin JT, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jul;27(7):455-9. Zhonghua Jie He He Hu Xi Za Zhi. 2004. PMID: 15312558 Clinical Trial. Chinese.

10

Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.

Fry AM, Goswami D, Nahar K, Sharmin AT, Rahman M, Gubareva L, Azim T, Bresee J, Luby SP, Brooks WA. Fry AM, et al. Lancet Infect Dis. 2014 Feb;14(2):109-18. doi: 10.1016/S1473-3099(13)70267-6. Epub 2013 Nov 22. Lancet Infect Dis. 2014. PMID: 24268590 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

142 results

Results by year